Critical Limb Ischemia Treatment Market to Grow with a CAGR of 7.25% through 2028
Rising
prevalence of diabetes brought on by an aging global population is expected to
drive the Global Critical Limb Ischemia Treatment Market growth in the forecast
period, 2024-2028.
According
to TechSci Research report, “Critical Limb Ischemia Treatment Market –
Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2028”, the Global Critical Limb Ischemia Treatment Market
stood at USD 3.86 Billion in 2022 and is anticipated to project robust growth
in the forecast period with a CAGR of 7.25% through 2028. The market for
critical limb ischemia will rise due to the rising prevalence of diabetes
brought on by an aging global population and improved critical limb ischemia
treatment options. In addition, despite the disease's complexity and low
visibility, businesses are actively working to produce critical limb ischemia medications
to meet the unmet needs of the condition. The condition is not properly
identified or treated, increasing morbidity, mortality, and expenses. A lack of
knowledge and other diseases with a similar presentation hampers the expansion
of the critical limb ischemia market. Along with the failure of medications in
clinical development, the evolution of the critical limb ischemia market is
also constrained by rigorous pricing and reimbursement regulations.
Furthermore, the accessibility of surgical techniques can make it challenging
for novel treatments to gain traction.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on
"Global Critical Limb Ischemia Treatment Market.”
The
lack of comprehensive knowledge regarding the epidemiology and etiology of the
disease has declined the development of successful therapy options. Leading
market participants for the treatment of critical limb ischemia consequently
reported a reduction in revenue due to the pandemic. The market has been
bouncing back from COVID-19, nevertheless, due to the relaxation of regulations
by governments worldwide. During the forecast period, the devices segment is
anticipated to hold a significant share of the worldwide critical limb ischemia
therapy market. Stents and dilation devices successfully dilate the artery
while safeguarding the arterial wall. These are the tools that are frequently
used to treat critical limb ischemia. Patients experience a higher quality of
life thanks to the low complication rates and the tremendous technical success
of dilation devices and stents. During the forecast period, the devices segment
is expected to be driven by these benefits. The growing number of FDA approvals
and patient preference for revascularization as the first line of treatment can
also be attributed to the segment's dominance.
The
Global Critical Limb Ischemia Treatment Market is segmented into Treatment, and
company.
Based
on the Devices, the Embolic Protection Devices segment is anticipated to
witness substantial market growth throughout the forecast period. The Global
Critical Limb Ischemia (CLI) Treatment Market is experiencing substantial
growth propelled by the widespread adoption of Embolic Protection Devices
(EPDs). These specialized devices play a pivotal role in enhancing the safety
and efficacy of endovascular interventions for critical limb ischemia by
preventing the migration of embolic debris during procedures. Embolic events,
where debris breaks loose and travels downstream, can exacerbate vascular
complications in CLI patients. EPDs act as a safeguard, capturing and removing
embolic material, thus minimizing the risk of distal embolization and
subsequent tissue damage.
Based
on the Drugs segment, the Antihypertensive Agents segment has been the dominant
force in the market. The Global Critical Limb Ischemia (CLI) Treatment Market
is experiencing growth driven by the integral role of Antihypertensive Agents
in managing vascular health. Antihypertensive medications, designed to lower
blood pressure, play a crucial role in preventing and managing conditions
associated with critical limb ischemia. Hypertension is a significant risk
factor for vascular diseases, and controlling blood pressure is paramount in
preventing further deterioration of peripheral arteries. As physicians
increasingly recognize the importance of managing cardiovascular risk factors
in CLI patients, antihypertensive agents have become cornerstone components of
comprehensive treatment strategies. These medications not only contribute to
blood pressure control but also help mitigate the progression of
atherosclerosis, a common underlying cause of critical limb ischemia.
Major companies operating in Global Critical Limb
Ischemia Treatment Market are:
- Medtronic Plc
- LimFlow SA
- Cynata Therapeutics Ltd
- Cardiovascular Systems, Inc.
- Eli Lilly and Company
- Abbott Laboratories
- Rexgenero Ltd.
- Cesca Therapeutics (ThermoGenesis
Holdings, Inc)
- Teva Pharmaceuticals
- Micro Medical Solutions
- Boston Scientific Corporation
Download Free Sample Report
Customers
can also request 10% free customization on this report.
“Additionally,
the growing prevalence of the risk factors which increase CLI incidence is
expected to boost the growth of the market. Various strategies adopted by the
market players such as product launches, mergers and acquisitions, and product
development are expected to support the market's expansion over the forecast
period. The rising company activities for developing bone graft substitute
products and the rising adoption of various business strategies such as
collaborations, mergers, and acquisitions are all anticipated to increase the
market growth over the forecast period. The increasing focus of the company to
develop technologically advanced devices and drugs to treat critical limb
ischemia is expected to augment the growth of the market.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Critical
Limb Ischemia Treatment Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Treatment (Drugs, Devices),
By Drugs (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents,
Antithrombotic Agents, Others), By Devices (Embolic Protection Devices,
Peripheral Dilatation System, Balloon Dilators, Vascular Stents), By Region, By
Competition”, has evaluated the future growth potential of Global Critical
Limb Ischemia Treatment Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Critical
Limb Ischemia Treatment Market.
Contact
Mr.
Ken Mathews
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel:
+13322586602
Email: [email protected]
Web: https://www.techsciresearch.com